Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib

Leukemia. 2005 Oct;19(10):1835-8. doi: 10.1038/sj.leu.2403848.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / metabolism
  • Benzamides
  • Cells, Cultured
  • Drug Resistance, Neoplasm*
  • Drug Therapy, Combination
  • Everolimus
  • Fusion Proteins, bcr-abl / genetics
  • Fusion Proteins, bcr-abl / metabolism*
  • Imatinib Mesylate
  • Immunosuppressive Agents / pharmacology*
  • Mice
  • Mutation / genetics
  • Piperazines / administration & dosage
  • Pyrimidines / administration & dosage
  • Sirolimus / administration & dosage
  • Sirolimus / analogs & derivatives*
  • Sirolimus / pharmacology

Substances

  • Benzamides
  • Immunosuppressive Agents
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Everolimus
  • Fusion Proteins, bcr-abl
  • Sirolimus